hVIVO Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 174

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $16.8M

  • Investors
  • 1

hVIVO General Information

Description

Developer of antiviral drugs and vaccines designed for respiratory and enteric diseases. The company offers testing of infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, enabling pharmaceutical and biotech sponsors to conduct human challenge trials with robust safety oversight, streamlined regulatory compliance, and comprehensive end-to-end operational and scientific support.

Contact Information

Website
www.hvivo.com
Formerly Known As
Retroscreen Virology Group, Open Orphan plc, Open Orphan
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 40 Bank Street, Floor 24
  • London E14 5NR
  • England, United Kingdom
+44 020
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 40 Bank Street, Floor 24
  • London E14 5NR
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

hVIVO Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 09-Dec-2019 $16.8M Completed Generating Revenue
7. PIPE 26-Nov-2015 Completed Generating Revenue
6. PIPE 14-Aug-2014 Completed Generating Revenue
5. IPO 03-May-2012 Completed Generating Revenue
4. Later Stage VC 16-May-2011 Completed Generating Revenue
3. Later Stage VC (Series B) 15-Oct-2009 Completed Generating Revenue
2. Later Stage VC (Series A) 24-Aug-2006 $1.89M $1.89M Completed Generating Revenue
1. University Spin-Out 01-Dec-1988 Completed Startup
To view hVIVO’s complete valuation and funding history, request access »

hVIVO Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 1
Series B
Ordinary 145,658 $0.001643 $2.93 $2.93 1x $2.93 4.72%
To view hVIVO’s complete cap table history, request access »

hVIVO Patents

hVIVO Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202114656-D0 Biomarker Inactive 13-Oct-2021
GB-202114655-D0 Biomarkers Inactive 13-Oct-2021
GB-201805472-D0 Biomarkers and methods for classifying subjects following viral exposure Inactive 03-Apr-2018
JP-2021507921-A Methods and compounds for the treatment or prevention of hypercytokine storms and severe influenza Active 22-Dec-2017
WO-2019122909-A1 Methods and compounds for the treatment or prevention of hypercytokinemia and severe influenza Inactive 22-Dec-2017 A61K31/437
To view hVIVO’s complete patent history, request access »

hVIVO Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

hVIVO Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aquarius Equity Partners Venture Capital Minority
Calculus Capital PE/Buyout Minority
IP Group Venture Capital Minority
Northern Initiatives Lender/Debt Provider Minority
Queen Mary University of London Endowment Limited Partner Minority
To view hVIVO’s complete investors history, request access »

hVIVO Investments & Acquisitions (8)

hVIVO’s most recent deal was a Merger/Acquisition with CRS Clinical Research Services for . The deal was made on 27-Aug-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CRS Clinical Research Services 27-Aug-2026 Merger/Acquisition BPO/Outsource Services
Cryo-Store 27-Feb-2025 Merger/Acquisition Other Pharmaceuticals and Biotechnology
CRS Clinical Research Services (Two Clinical Research Units) 29-Jan-2025 Merger/Acquisition Other Pharmaceuticals and Biotechnology
CHIMagents 15-Jul-2020 Merger/Acquisition Other Healthcare Services
Venn Life Sciences 28-Jun-2019 Merger/Acquisition Other Healthcare Services
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

hVIVO Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Venn Life Sciences Breda, Netherlands 2007
Cryo Store Joure, Netherlands 1999

hVIVO FAQs

  • When was hVIVO founded?

    hVIVO was founded in 1988.

  • Where is hVIVO headquartered?

    hVIVO is headquartered in London, United Kingdom.

  • What is the size of hVIVO?

    hVIVO has 174 total employees.

  • What industry is hVIVO in?

    hVIVO’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is hVIVO a private or public company?

    hVIVO is a Private company.

  • What is the current valuation of hVIVO?

    The current valuation of hVIVO is .

  • What is hVIVO’s current revenue?

    The current revenue for hVIVO is .

  • How much funding has hVIVO raised over time?

    hVIVO has raised $119M.

  • Who are hVIVO’s investors?

    Aquarius Equity Partners, Calculus Capital, IP Group, Northern Initiatives, and Queen Mary University of London Endowment have invested in hVIVO.

  • When was hVIVO acquired?

    hVIVO was acquired on 09-Dec-2019.

  • Who acquired hVIVO?

    hVIVO was acquired by Venn Life Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process